To provide the information your oncologist is not telling you or doesn't have the time to!
Explore the world of melanoma, a formidable form of skin cancer, through our dedicated “Melanoma” subcategory. Gain valuable insights into the causes, risk factors, and early detection of melanoma. Dive deep into the latest advancements in melanoma treatment options, including surgical interventions, immunotherapy, and targeted therapies. Whether you’re seeking information for prevention, diagnosis, or support, this subcategory is your trusted resource for comprehensive knowledge about melanoma. Together, we’ll navigate this journey toward melanoma awareness and effective management.
Embarking on the tumultuous journey that is stage IV melanoma, both patients and healthcare providers often find themselves in an intricate dance of vulnerability, resilience, and human connection. This is the poignant tale of a young man’s persistent battle against melanoma, his remarkable perseverance through a myriad of treatments, and the eventual moment of triumph …
This post is based on the interesting results published by Routy et al. Nature July 2023. I am hoping that we will soon open a protocol using FMT in cancer patients and I will announce once we’re site activated at the Orlando Health Cancer Institute. The revolutionary world of cancer treatment is once again on …
Uveal melanoma, a rare and aggressive form of eye cancer, has just witnessed a groundbreaking development in its treatment landscape. The Food and Drug Administration (FDA) recently granted approval to the HEPZATO KIT, an innovative liver-directed therapy that offers new hope to adult patients with uveal melanoma and unresectable hepatic metastases.
This is a new clinical trial using Tebentafusp alone or in combination with Pembrolizumab is now open and actively enrolling at the Orlando Health Cancer Institute for patients dealing with Metastatic Cutaneous Melanoma. Tebentafusp is currently FDA approved for all patients with Metastatic Uveal Melanoma. Detailed information can be found here at clinicaltrials.gov and NEJM …
ASCO 2023 was an incredible conference and I had completely enjoyed the networking, presentations, and evening meetings. Here are two melanoma clinical trials that we had also participated in enrollment at the Orlando Health Cancer Institute. It is incredibly exciting to see patients do better with improved responses as well as improved odds of not …
Replaying this post as a reminder that this study is enrolling at multiple sites globally. More detailed information can also be seen here at clinicaltrials.gov as well as the sponsor Iovance. All information and data stated in this article are available publicly through online resources that I’ve also linked below for reference. This new trial …
mRNA technology has revolutionized the world of medicine. Known for its role in the creation of COVID-19 vaccines, mRNA has been lauded as a game-changer in the fight against infectious diseases. But mRNA’s impact extends far beyond pandemic control. It’s now making waves in another critical area of healthcare: cancer treatment and prevention. mRNA stands …
I am really excited about this new protocol specifically for patients with MAGE4+ HLA restricted SPEAR TILs for Metastatic Melanoma, Non-small Cell Lung Cancer, Head Neck cancer, Ovarian, Endometrial, and Urothelial cancers. The Gastric and Esophageal Cancer cohorts are closed. The social media material seen here was approved both the sponsor and IRB. Please contact …
This post was written by our melanoma/sarcoma nurse navigator Ashlee Jones. She is highly respected by all members of my team to include the nurses, pharmacist, staff, research team, and physicians! I’ve always felt that new patients diagnosed with cancer can initially have a rough start in the journey given the new diagnosis, the array …
A recent publication by Dr Eroglu et al. in Cancer can be found here! Hope this articles helps! As an oncologist, my days are filled with fascinating and challenging cases, but one recent patient in particular caught my attention. He was a young man who had just undergone surgery to remove high-risk Stage IIC malignant …